ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient

Zou, Rui; Zhou, Xiao; Liu, Hailing; Wang, Peng; Xia, Fan; Kang, Liqing; Yu, Lei; Wu, Depei*; Jin, Zhengming*; Qu, Changju*苏州大学; 1
Cancer Research and Treatment2023-10DOI: 10.4143/crt.2023.371
2被引3阅读
引用收藏
分享

摘要

Primary central nervous system lymphoma (PCNSL) is a rare and aggressive non-Hodgkin's lymphoma that affects the brain, eyes, cerebrospinal fluid, or spinal cord without systemic involvement. The outcome of patients with PCNSL is worse compared to patients with systemic diffuse large B-cell lymphoma. Given potential mortality associated with severe immune effector cell-associated neuro-toxicity syndrome (ICANS), patients with PCNSL have been excluded from most clinical trials involving chimeric antigen receptor T-cell (CAR-T) therapy initially. Here, we report for the first time to apply decitabine-primed tandem CD19/CD22 dual-targeted CAR-T therapy with programmed cell death-1 (PD-1) and Bruton's tyrosine kinase (BTK) inhibitors maintenance in one patient with multiline-resistant refractory PCNSL and the patient has maintained complete remission (CR) for a 35-month follow-up period. This case represents the first successful treatment of multiline resistant refractory PCNSL with long-term CR and without inducing ICANS under tandem CD19/ CD22 bispecific CAR-T therapy followed by maintenance therapy with PD-1 and BTK inhibitors. This study shows tremendous potential in the treatment of PCNSL and offers a look toward ongoing clinical studies.

学科与关键词

关键词
Chimeric antigen receptor T-cell therapyPrimary central nervous system lymphomaDiffuse large B-cell lymphomaCD19/CD22Decitabine
相关
加载中…
  • CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma
    Liu, Rui; Cheng, Qian; Kang, Liqing; Wang, Erhua; Li, Ying; Zhang, Jian; Xiao, Han; Zhang, Yi; Chu, Ling; Chen, Xin; Zhang, Chang; Tan, Jingwen; Xu, Nan; Li, Minghao; Yu, Lei; Li, Xin*Human Gene Therapy, 2022, 33(5-6): 318-329.被引 9
  • Efficacy and Safety of Orelabrutinib-Containing Regime (TORM) As First-Line Therapy in Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis
    Wu, Shaojie; Tu, Sanfang; Zhou, Zhenjun; Sun, Xinlin; Wu, Anqin; Wang, Lei; Li, Yuhua65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
  • Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use
    Chen, Feili; Pang, Diwen; Guo, Hanguo; Ou, Qiuxiang; Wu, Xue; Jiang, Xinmiao; Wei, Xiaojuan; Liu, Sichu; Huang, Ling; Liang, Zhanli; Zhou, Dong*; Li, Wenyu*Cancer Medicine, 2020, 9(22): 8676-8684.被引 21
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Research and Treatment
发表日期
2023-10
卷期
第 55 卷, 第 4 期
页码
1363-1368
DOI
10.4143/crt.2023.371
语言
ENGLISH
成果收录
SCIE
资助标注
National Key R&D Program of China [2016YFC0902800]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); National Natural Science Foundation of China [81400155]; Jiangsu Natural Science Foundation of China [BK20140374]; Top-notch young health talents, 5th Suzhou health professionals program [GSWS2019035]; National Clinical Research Center for hematologic disease [2021ZKMC01]

作者

  • Z

    Zou, Rui (第一作者)

    1 · soochow univ

  • Z

    Zhou, Xiao

查看全部 10 位作者收起作者
  • L

    Liu, Hailing

  • W

    Wang, Peng

    1 · soochow univ

  • X

    Xia, Fan

    1 · soochow univ

  • K

    Kang, Liqing

  • Y

    Yu, Lei

  • W

    Wu, Depei (通讯)

    1 · soochow univ

  • J

    Jin, Zhengming (通讯)

    1 · soochow univ

  • Q

    Qu, Changju (通讯)

    1 · soochow univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417